



Exactech Announces FDA Clearance of Connexion GXL Enhanced Polyethylene Hip Acetabular Liner

Gainesville, FL, October 11, 2005 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that the company's new Connexion™ GXL enhanced polyethylene acetabular liners for its AcuMatch® A-Series system has received 510(k) clearance from the U.S. Food and Drug Administration. The product launch is underway and will continue for the next several months.

Gary Miller, Ph.D., Exactech's executive vice president of research and development, said, "Connexion GXL polyethylene is processed with an elevated level of irradiation, which testing has demonstrated significantly reduces polyethylene wear while maintaining an appropriate level of fracture toughness. The science behind the AcuMatch A-Series design and our comprehensive selection of femoral stems combine with this new technology to reduce polyethylene wear debris associated with osteolysis. Connexion GXL is the latest in a broad range of product and material development programs at Exactech that are advancing bearing surface technology to increase the longevity of total hip prostheses."

Exactech CEO Bill Petty said, "Connexion GXL complements the press fit femoral stems that were successfully launched this year as the first element of Exactech's Novation™ Comprehensive Hip System. This combination of enhanced polyethylene and press fit stems addresses more than 50% of the total hip market. We expect it will contribute to our hip growth in the coming year."

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech's orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and in more than 25 countries in Europe, Asia, Australia and Latin America.

An investment profile on Exactech may be found at <http://www.hawkassociates.com/exactech/profile.htm>.

Additional information about Exactech, Inc. can be found at <http://www.exac.com>. An online virtual investor relations kit containing Exactech press releases, SEC filings, current price

quotes, stock charts and other useful information for investors can be found on the Hawk Associates website, <http://www.hawkassociates.com>. Investors may contact Chief Financial Officer Jody Phillips at (352) 377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at (305) 451-1888, e-mail: info@hawkassociates.com.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third-party manufacturers to produce components on a basis that is cost-effective to the company, market acceptance of the company's products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.